# Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

> **NCT00266526** · PHASE2 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG**

## Conditions studied

- Birch Pollen Allergy

## Interventions

- **BIOLOGICAL:** Recombinant birch pollen

## Key facts

- **NCT ID:** NCT00266526
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2004-07
- **Final completion:** 2005-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266526, "Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00266526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*